Home > Boards > US OTC > Medical - Healthcare >

Decision Diagnostics Corp. (DECN)

DECN RSS Feed
Add DECN Price Alert      Hide Sticky   Hide Intro
Moderator: pumper_stumper, ernie44, IPwatcher
Search This Board: 
Last Post: 1/18/2022 3:54:01 PM - Followers: 401 - Board type: Free - Posts Today: 3

 

     $DECN       
https://www.otcmarkets.com/stock/DECN/profile

                                                          

On December 18, 2020, the SEC and US Dept of Justice, announced actions against DECN due to alledged false claims about the supposed Covid-19 test being developed.

https://www.sec.gov/litigation/complaints/2020/comp-pr2020-327.pdf

On April 23, 2020, the SEC announced an action against DECN, suspending trading in the company's stock for two weeks.  There is currently a SEC court case ongoing where the SEC has identified the many reasons for the suspension.

https://www.otcmarkets.com/stock/DECN/news/SEC-Suspension-of-Trading?id=260085
 

DECN Earnings History

2021 Q1-Q3 - $1,374,707
  2020 - $
29,668,622-
2019 - $
3,132,295-
2018 - $2,240,220-
2017 - $2,991,404-
2016 - $2,967,357-
2015 - $2,771,345-
2014 - $1,841,010-

Total - $46,986,960-



                                     
Decision Diagnostics Corp. is a nationwide prescription and non-prescription diagnostics and home testing products distributor. We market our GenUltimate, GenSure, PetSure (test strips for dogs and cats) and GenChoice (in FDA 510(k) review), our panacea GenUltimate TBG glucose test strips and meter (in 3rd party testing), our GenPrecis test strips and meter (for private label sale), and our GenUltimate 4Pets glucose test strips and meter for the diabetic testing of dogs, cats and horses. We are also FDA approved and have complete R&D and manufacturing facilities in South Korea. We made the the first alternative glucose testing strips sold to the market in this decade and the first alternative test strip products sold into the market since early 2008.

                                                                                             
                                                                        



                                      

                                                                                                
               

Keith Berman, CEO of DECN commented, "GenViro for the Coronavirus (covid19) began as an outgrowth of our GenUltimate TBG product line. What makes the testing for the Coronavirus possible, and the GenUltimate TBG special, is the company's Impedance measurement technology.

https://www.frontiersin.org/articles/10.3389/fmicb.2015.00940/full

While infectious disease testing and management has not previously been a part of our business model, we seized on this "do good" opportunity because our "Gen" line of products are and have been manufactured since 2016 in what is ground zero for Coronavirus (covid19) in Daegu, Korea. The company will have available samples of the blood of those previously infected available for testing as the company quickly converts its GenUltimate TBG methods and Precise meter, into a precise infectious disease testing device for the screening for Coronavirus."

                                                    



Read Recent Press Releases » 

Review Recent Financial Reports »

Visit PharmaTech Solutions, Inc. »

                                 

 


Mod Cash4 Updated Ibox 3/11/2020

NEWS
https://www.otcmarkets.com/stock/DECN/news


 

GenViro! 12-Month Forecast

Number of Months

1

2

3

4

5

6

7

8

9

10

11

12

SUM

Year 1

Apr-20

May-20

Jun-20

Jul-20

Aug-20

Sep-20

Oct-20

Nov-20

Dec-20

Jan-21

Feb-21

Mar-21

 
                           

New Facility Customers

0

0

0

0

0

5000

5000

5000

5000

5000

5000

5000

 

Retained Facilities

0

0

0

0

0

0

5000

10000

15000

20000

25000

30000

 

Total Facility Customers

0

0

0

0

0

5000

10000

15000

20000

25000

30000

35000

35,000

Kits Consumed

0

0

0

0

0

15,000,000

30,000,000

45,000,000

60,000,000

75,000,000

90,000,000

105,000,000

420,000,000

We are not resting our laurels with our GenViro development. Later product entries will be test methods for Polio, Ebola (Marburg), Bird Flu, and SARS. The cost of our test kits will be sold in a price range of $4.95 to $7.95 per use. The Coronavirus kit will be sold for $6.95. Each kit sold will carry enough diagnostic for two tests, a primary test, and a test in reserve in case of human error in administrating the primary test. We plan to provide our diagnostics initially for use at hospitals, doctors' offices, and clinics. Once production ramps up, we will offer testing kits and meters to patients for testing at-home.

Mr. Berman concluded, "As you might imagine with a product announcement of such importance, we have been contacted by a number of potential partners for our kit, as well as companies who were not chosen last time to proceed past the proposition stage. The company's first choice for partnering will be a company that made "the cut" last time for our GenUltimate! TBG product. We will discuss partnering potential in a coming release. For the moment, the company is content calling on big box and long term care chains through its existing distributors and agents."

DECN also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leding Zoetis Alpha Trak meter system as well as the GenUltimate! 4Pets Test strip and Avantage! meter. The company has also just introduced its GenExpidient! Universal Translator for bio-sensor devices of different manufacture. A GenExpidient! device will be included in every Covid19 kit. Having such a device will lower the incidence of cleaning and disinfecting the GenViro! meter.

ABOUT DECISION DIAGNOSTICS CORP

Decision  

Forward-Looking Statements:

This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of March 11 2020, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

CONTACT INFORMATION:

Decision Diagnostics Corp.
Keith Berman (805) 446-2973

info@decisiondiagnostics.co
www.genultimate.com
www.genultimatetbg.com
www.petsureteststrips.com
www.pharmatechdirect.com

SOURCE: Decision Diagnostics Corp.



View source version on accesswire.com:
https://www.accesswire.com/579985/DECN-Provides-First-Looks-At-Its-GenViroTM-Corona-Virus-Screening-Kit-First-Year-Product-Forecast-of-420-Million-Kits-with-Sales-Beginning-Late-3Q-2020


 

SEC Charges Biotech Company and CEO With Fraud Concerning COVID-19 Blood Testing Device
FOR IMMEDIATE RELEASE

2020-327

Washington D.C., Dec. 18, 2020 —
The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics' securities on April 23, 2020.

The SEC's complaint alleges that Decision Diagnostics and Berman seized upon the global pandemic through a series of press releases that falsely claimed Decision Diagnostics had developed a finger prick blood test that could detect Covid-19 in less than a minute. According to the complaint, from March 2020 to at least June 2020, Decision Diagnostics and Berman made false and misleading statements about the existence of Decision Diagnostics' Covid-19 device and progress towards FDA emergency use authorization. As alleged, at the time of these claims, Decision Diagnostics lacked a proven method for detecting the virus and had no physical testing device. Further, its advisors had warned that the testing kit they were trying to manufacture would not work as Decision Diagnostics had described. The complaint also alleges that the statements created the misleading impression that the test was soon to be introduced to the market and led to surges in the price and trading volume of Decision Diagnostics' stock.

"During this unprecedented time, when the need for truthful disclosures concerning Covid-19 tests is of vital importance, Decision Diagnostics and its CEO allegedly misled investors by claiming to have made a working test device when all they had was an idea that had not materialized into a product," said Stephanie Avakian, Director of the Division of Enforcement. "With the onset of the global pandemic, we quickly pivoted to identify potential areas of fraud. This case is another example of how the Commission will hold accountable those who exploit the pandemic to harm investors."

"In our complaint, we allege that Decision Diagnostics and Berman repeatedly made baseless representations to the investing public about market-moving events like progress in obtaining FDA approval and having breakthrough technology," said Anita B. Bandy, Associate Director of the Division of Enforcement. "Today's filing is a credit to the dedicated SEC staff, who continued to investigate after the trading suspension and quickly uncovered the alleged fraud."

The complaint, filed in the U.S. District Court for the Southern District of New York, charges Decision Diagnostics and Berman with violating antifraud provisions of the securities laws. The SEC is seeking a court order permanently enjoining both Decision Diagnostics and Berman from directly or indirectly violating those provisions and ordering them to pay civil penalties.

The Department of Justice's Market Integrity and Major Frauds Unit announced today that parallel criminal charges against Berman were also filed in the U.S. District Court for the District of Columbia.

The SEC's investigation, which is continuing, has been conducted by Ernesto Amparo, Carlisle Perkins and Lesley Atkins and supervised by Jeff Leasure and Ms. Bandy with invaluable assistance by Margaret A. Cain of the Office of Market Intelligence and Hane L. Kim of the Microcap Fraud Task Force, both members of the SEC's Coronavirus Steering Committee. The litigation will be handled by James Carlson, David Misler and supervised by Tom Bednar. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.

https://www.sec.gov/news/press-release/2020-327

https://www.sec.gov/litigation/09/complaints/2020/comp-pr2020-327.pdf

 
DECN SECURITY DETAILS

Share Structure

 
Authorized Shares
494,995,000
 
Outstanding Shares

11/12/21 - 358,500,583
09/30/21 - 357,780,503
12/17/20 - Berman arrested by FBI

12/11/20 - 349,741,793
11/06/20 - 332,025,278
10/09/20 - 325,752,685
09/11/20 -  313,434,787
08/07/20 - 305,063,608
07/10/20 - 302,663,608
05/15/20 - 267,213,123
04/03/20 - 212,000,000
03/31/20 - 199,792,833
03/06/20 - 159,999,161
12/31/19 - 156,679,161
12/31/18 - 134,551,840
12/31/17 - 110,241,640
12/31/16 - 84,639,908 

 
 
Restricted

07/10/2020 - 5,969,436
10/09/2020 - 9,983,981
12/10/2021 - 18,742,771
 
Unrestricted
12/10/2021 - 339,757,812
 

 

 
 
 
DECN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#96281  Sticky Note Please take new Survey about Berman trial on pumper_stumper 12/28/21 12:03:29 PM
#94285  Sticky Note LINKS TO COURT DOCUMENTS IN BERMAN/DECN SECURITIES FRAUD PROCEEDINGS: IPwatcher 01/16/21 08:53:26 PM
#96439   No, the shareholders have to hold Berman harmless PlutoniumImplosion07 01/18/22 03:54:01 PM
#96438   seems like a lost cause, are Berman's attorneys Johnny_C 01/18/22 07:36:25 AM
#96437   Talk about "delusions of grandeur"? Multiple personalities via Hopefull17 01/18/22 07:17:26 AM
#96436   Not sure why anyone would even think the Johnny_C 01/17/22 10:43:02 AM
#96435   it seems apparent the same rogue message board Johnny_C 01/17/22 10:38:20 AM
#96434   As Berman didn't own that many shares, Johnny_C 01/17/22 10:32:23 AM
#96433   By the time it reached the FBI, KB Johnny_C 01/17/22 10:29:49 AM
#96432   was seaeching SEC for Berman---seems he is ok IPwatcher 01/16/22 06:12:51 PM
#96431   was seaeching SEC for Berman---seems he is ok ernie44 01/16/22 05:21:10 PM
#96428   The non-believers only read the evidence they cite PlutoniumImplosion07 01/16/22 12:50:00 AM
#96425   Hey Keith, want to update this part for us? pumper_stumper 01/15/22 03:39:13 PM
#96423   Didn’t Bozo submit one to the Xdrive competition? IPwatcher 01/13/22 07:02:06 PM
#96422   No he didn't. The next round of pumper_stumper 01/13/22 04:03:15 PM
#96421   What would really have livened things up would Johnny_C 01/13/22 03:40:39 PM
#96420   That doc was just a tool, talking up Johnny_C 01/13/22 03:38:44 PM
#96418   Remember "Thank you CBS"? I believe it pumper_stumper 01/12/22 01:16:42 PM
#96417   Sure would be an exciting message board if Johnny_C 01/12/22 11:44:35 AM
#96416   Tell you what would liven it up right? IPwatcher 01/12/22 06:59:43 AM
#96415   its getting beyond the point of a poor show-----boooooorrrriiinnnnggg ernie44 01/11/22 10:24:01 PM
#96414   You forgot the pat on the backs deserved IPwatcher 01/11/22 07:57:27 PM
#96413   LOL... Good answer. You forgot the Johnny_C 01/11/22 07:20:45 PM
#96412   WHATS PUMPER JONNY C AND THEIR ILK GOING IPwatcher 01/11/22 06:05:46 PM
#96410   "It is all moot anyway. He will lose pumper_stumper 01/11/22 01:31:21 PM
#96409   The only way this goes to trial is Johnny_C 01/11/22 01:30:53 PM
#96408   I wouldn't hold your breath on anybody else Johnny_C 01/11/22 01:29:23 PM
#96407   Criminal cases offer defendants a bit more protection Johnny_C 01/11/22 01:26:22 PM
#96406   I don't really have much of an opinion Johnny_C 01/11/22 01:21:21 PM
#96405   IMO, defense counsel knows it will not prevail Hopefull17 01/11/22 12:40:34 PM
#96404   I wonder if MF Berman used a GenViro Hopefull17 01/11/22 12:35:05 PM
#96403   HERZOG'S were our neigbors when we were poor--they ernie44 01/11/22 12:34:51 PM
#96402   So then all this discussion of all this IPwatcher 01/11/22 12:03:08 PM
#96401   You yourself said, it won't take anything to pumper_stumper 01/11/22 10:48:13 AM
#96400   What "protections" exactly are you referring to that IPwatcher 01/11/22 10:26:18 AM
#96399   What "protections" exactly are you referring to that pumper_stumper 01/11/22 09:53:37 AM
#96398   Hard to believe it is still operating. Maybe Johnny_C 01/11/22 09:45:59 AM
#96397   Much easier to take action after a proven Johnny_C 01/11/22 09:42:50 AM
#96396   as it won't take much in SEC fines IPwatcher 01/11/22 09:39:42 AM
#96395   True, the less informed think that the SEC pumper_stumper 01/11/22 09:09:01 AM
#96394   Well, we also need to get the popcorn Johnny_C 01/11/22 08:22:03 AM
#96393   This legal effort is equivalent to watching a IPwatcher 01/11/22 05:01:13 AM
#96392   This is the "beauty" of following DECN. pumper_stumper 01/10/22 10:30:38 PM
#96391   Correct me if I am wrong, but slightly Johnny_C 01/10/22 09:39:18 PM
#96390   LOL, like I stated before, at best all Johnny_C 01/10/22 09:36:02 PM
#96389   One thing is for sure, supplying a bogus Johnny_C 01/10/22 09:34:07 PM
#96388   The test is a joke, why they would Johnny_C 01/10/22 09:31:44 PM
#96387   "Mr. Berman now has a confirmed case of Covid" IPwatcher 01/10/22 08:07:16 PM
#96386   "I heard people downplaying the kit. The kit, pumper_stumper 01/10/22 07:35:07 PM
#96385   "the defendant will slightly modify Exhibit N to IPwatcher 01/10/22 07:07:46 PM
#96384   Anyone want to try an analogy of Berman's pumper_stumper 01/10/22 06:26:52 PM
#96383   NEWS! Berman has Covid-19! Also news, surprising pumper_stumper 01/10/22 05:57:58 PM
PostSubject
Consent Preferences